25.08.2014 - Gene and cell therapy company Oxford Biomedica plc has appointed Paul Blake as Chief Development Officer.
Most recently, Paul was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a Canada-based biopharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014. Paul was a Member of the Board at Memory Pharmaceutical, Inc. and founding Board member of Protez Pharmaceuticals, which were later acquired by Roche and Novartis, respectively. He was also Director of ViaCell and held senior management positions at Cephalon Inc. He is a fellow of the Royal College of Physicians, a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and also a fellow of the American College of Clinical Pharmacology.
Effective September 1st, Blake will take over responsibility for the clinical development of Oxford Biomedica’s therapy pipeline. Blake will also remain a member of the company’s board, which he joined in early 2010.http://www.european-biotechnology-news.com/people/bio-people/2014/paul-blake.html